Stock market today: S&P 500 rides Apple-led tech rally to close higher
Scott Boyle, the Chief Business Officer of C4 Therapeutics, Inc. (NASDAQ:CCCC), recently executed several stock transactions, according to a recent SEC filing. The company, currently trading near its 52-week low of $3.15, has seen its stock decline over 45% in the past six months, according to InvestingPro data. Notably, Boyle sold shares totaling $3,650, with prices for these transactions at $3.15 per share. These sales were part of a trading plan adopted on March 13, 2024, under Rule 10b5-1. While the company maintains strong liquidity with a current ratio of 6.31, InvestingPro analysis indicates the stock is currently undervalued.
In addition to the sales, Boyle acquired 56,500 shares at no cost, reflecting restricted stock units that vest in annual installments starting February 14, 2026. Furthermore, Boyle engaged in transactions involving shares withheld to satisfy tax obligations related to the vesting of restricted stock units, which totaled $13,082, with prices ranging between $3.18 and $3.20 per share.
Boyle also received stock options to purchase 84,700 shares, which will vest in monthly installments beginning March 14, 2025. Following these transactions, Boyle’s direct ownership of C4 Therapeutics stock stands at 107,805 shares. For deeper insights into insider trading patterns and 10 additional key metrics, including analyst price targets ranging from $4 to $50, consider exploring InvestingPro.
In other recent news, C4 Therapeutics has made significant strides in its clinical trials and strategic developments. The company announced the progress of its key 2025 clinical trials, including those for cemsidomide, a drug candidate for multiple myeloma and non-Hodgkin’s lymphoma, and CFT1946 for BRAF V600X solid tumors. Additionally, early-stage trials of cemsidomide have shown encouraging data, with Jefferies and Stifel analysts maintaining a buy rating on the company, citing potential advantages in efficacy and safety.
Moreover, C4 Therapeutics has strengthened its leadership team with the appointment of Steve Hoerter to its Board of Directors. Hoerter brings over 30 years of experience in oncology commercialization, having held roles at Deciphera Pharmaceuticals (NASDAQ:DCPH) and Agios Pharmaceuticals, among others.
These recent developments highlight C4 Therapeutics’ commitment to advancing its pipeline of novel degraders and transitioning into a fully integrated biotechnology company. The company’s current financial resources are expected to fund operations into 2027, supporting the development of orally bioavailable degraders for oncology and non-oncology targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.